{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:43:24Z","timestamp":1791924204664,"version":"4.3.4"},"reference-count":143,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.kint.2020.11.010","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T23:04:49Z","timestamp":1610319889000},"page":"570-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Management of acute kidney injury in symptomatic multiple myeloma"],"prefix":"10.1016","volume":"99","author":[{"given":"Frank","family":"Bridoux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Belmouaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Royal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samih H.","family":"Nasr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Paul","family":"Fermand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2020.11.010_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1016\/j.kint.2020.11.010_bib2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2020.11.010_bib3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2141.2006.06235.x","article-title":"Monoclonal gammopathy of undetermined significance","volume":"134","author":"Kyle","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.kint.2020.11.010_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.11.010_bib5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/088506669501000304","article-title":"Hyperviscosity syndrome","volume":"10","author":"Gertz","year":"1995","journal-title":"J\u00a0Intensive Care Med"},{"key":"10.1016\/j.kint.2020.11.010_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nrneph.2011.168","article-title":"The pathogenesis and diagnosis of acute kidney injury in multiple myeloma","volume":"8","author":"Hutchison","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib7","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood-2012-07-445304","article-title":"Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant","volume":"120","author":"Leung","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib8","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2018-04-839480","article-title":"Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications","volume":"132","author":"Fermand","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib9","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib10","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/ki.2014.408","article-title":"Diagnosis of monoclonal gammopathy of renal significance","volume":"87","author":"Bridoux","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.11.010_bib11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib12","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.kint.2020.11.010_bib13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.kint.2020.11.010_bib14","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0025-6196(25)00115-6","article-title":"Multiple myeloma: review of 869 cases","volume":"50","author":"Kyle","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.kint.2020.11.010_bib16","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2020.11.010_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1600-0609.1994.tb00190.x","article-title":"The Nordic Myeloma Study Group. Renal function in newly diagnosed multiple myeloma\u2014a demographic study of 1353 patients","volume":"53","author":"Knudsen","year":"1994","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.kint.2020.11.010_bib18","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution","volume":"158","author":"Blad\u00e9","year":"1998","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.kint.2020.11.010_bib19","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1038\/bcj.2015.20","article-title":"Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma","volume":"5","author":"Gonsalves","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.kint.2020.11.010_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/ejh.12164","volume":"91","author":"Terpos","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.kint.2020.11.010_bib21","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3109\/10428194.2013.820284","article-title":"Application of RIFLE criteria in patients with multiple myeloma with acute kidney injury: a 15-year retrospective, single center, cohort study","volume":"55","author":"Shi","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.kint.2020.11.010_bib22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/ndt\/gfv283","article-title":"Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients","volume":"31","author":"Ecoti\u00e8re","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2020.11.010_bib23","first-page":"143","article-title":"Urinary tract obstruction due to extramedullary plasmacytoma: report of two cases","volume":"2","author":"Big\u00e9","year":"2009","journal-title":"NDT Plus"},{"key":"10.1016\/j.kint.2020.11.010_bib24","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2017.17924","article-title":"Effect of high-cutoff hemodialysis vs conventional hemodialysis on hemodialysis independence among patients with myeloma cast nephropathy: a randomized clinical trial","volume":"318","author":"Bridoux","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2020.11.010_bib25","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1200\/JCO.20.00298","article-title":"Randomized trial comparing double versus triple bortezomib-based regimen in patients with multiple myeloma and acute kidney injury due to cast nephropathy","volume":"38","author":"Bridoux","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2020.11.010_bib26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3324\/haematol.2017.178103","article-title":"Outcome and survival of myeloma patients diagnosed 2008-2015: real-world data on 4904 patients from the Swedish Myeloma Registry","volume":"103","author":"Blimark","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2020.11.010_bib27","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3109\/10428194.2011.597906","article-title":"Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens","volume":"52","author":"Eleftherakis-Papapiakovou","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.kint.2020.11.010_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/00005792-198703000-00004","article-title":"Multiple myeloma and severe renal failure: a clinicopathologic study of outcome and prognosis in 34 patients","volume":"66","author":"Rota","year":"1987","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kint.2020.11.010_bib29","first-page":"222","article-title":"Renal histological lesions and clinical syndromes in multiple myeloma","volume":"27","author":"Pasquali","year":"1987","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2020.11.010_bib31","doi-asserted-by":"crossref","first-page":"E5","DOI":"10.1016\/S0272-6386(99)70326-4","article-title":"Acute renal failure from multiple myeloma precipitated by ACE inhibitors","volume":"33","author":"Rabb","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2020.11.010_bib32","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1053\/j.ajkd.2011.12.028","article-title":"Clinicopathologic correlations in multiple myeloma: a case series of 190 patients with kidney biopsies","volume":"59","author":"Nasr","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2020.11.010_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4103\/0973-1482.63570","article-title":"Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review","volume":"6","author":"Weide","year":"2010","journal-title":"J\u00a0Cancer Res Ther"},{"key":"10.1016\/j.kint.2020.11.010_bib34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2020.11.010_bib35","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic microangiopathy associated with monoclonal gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.11.010_bib36","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/ckj\/sfv059","article-title":"Thrombotic microangiopathy associated with proteasome inhibitors","volume":"8","author":"Lodhi","year":"2015","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.kint.2020.11.010_bib37","doi-asserted-by":"crossref","first-page":"E348","DOI":"10.1002\/ajh.24447","article-title":"Proteasome inhibitor associated thrombotic microangiopathy","volume":"91","author":"Yui","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2020.11.010_bib38","doi-asserted-by":"crossref","first-page":"E53","DOI":"10.1002\/ajh.24662","article-title":"Ixazomib-induced thrombotic microangiopathy","volume":"92","author":"Yui","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2020.11.010_bib39","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1080\/10428194.2018.1515941","article-title":"Two cases of reversible Fanconi syndrome induced by lenalidomide","volume":"60","author":"Wesner","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.kint.2020.11.010_bib40","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1634\/theoncologist.2010-0070","article-title":"Lenalidomide-induced acute interstitial nephritis","volume":"15","author":"Lipson","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.kint.2020.11.010_bib41","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1093\/ndt\/gfv222","article-title":"Bortezomib-induced acute interstitial nephritis","volume":"30","author":"Cheungpasitporn","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2020.11.010_bib42","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.21873\/anticanres.11274","article-title":"High risk of tumor lysis syndrome in symptomatic patients with multiple myeloma with renal dysfunction treated with bortezomib","volume":"36","author":"Oiwa","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.kint.2020.11.010_bib43","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V98.3.714","article-title":"The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden","volume":"98","author":"Comenzo","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib44","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2005-11-4419","article-title":"Role of the monoclonal kappa chain V domain and reversibility of renal damage in a transgenic model of acquired Fanconi syndrome","volume":"108","author":"Sirac","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib45","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1172\/JCI46490","article-title":"Mechanism and prevention of acute kidney injury from cast nephropathy in a rodent model","volume":"122","author":"Ying","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2020.11.010_bib46","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.2215\/CJN.02560316","article-title":"Paraprotein-related kidney disease: kidney injury from paraproteins\u2014what determines the site of injury?","volume":"11","author":"Doshi","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib47","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.kint.2016.09.004","article-title":"Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management","volume":"91","author":"Bridoux","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.11.010_bib48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/nrneph.2018.8","article-title":"Animal models of monoclonal immunoglobulin-related renal diseases","volume":"14","author":"Sirac","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib49","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1182\/blood-2018-09-872028","article-title":"Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study","volume":"133","author":"Joly","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib50","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/j.ajkd.2015.03.035","article-title":"Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients","volume":"66","author":"Chauvet","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2020.11.010_bib51","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjh.14279","article-title":"Renal disease related to Waldenstr\u00f6m macroglobulinaemia: incidence, pathology and clinical outcomes","volume":"175","author":"Vos","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.kint.2020.11.010_bib52","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2215\/CJN.13041117","article-title":"Kidney involvement of patients with Waldenstr\u00f6m macroglobulinemia and other IgM-producing B cell lymphoproliferative disorders","volume":"13","author":"Higgins","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib53","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3324\/haematol.2015.128793","article-title":"Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience","volume":"100","author":"Strati","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2020.11.010_bib54","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/00005792-200005000-00002","article-title":"Adult Fanconi syndrome secondary to light chain gammopathy: clinicopathologic heterogeneity and unusual features in 11 patients","volume":"79","author":"Messiaen","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.kint.2020.11.010_bib55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2003-10-3400","article-title":"Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma","volume":"104","author":"Ma","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib56","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1681\/ASN.2015020185","article-title":"Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era","volume":"27","author":"Stokes","year":"2016","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib57","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/leu.2016.195","article-title":"Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients","volume":"31","author":"Vignon","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.kint.2020.11.010_bib58","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1053\/j.ajkd.2010.06.021","article-title":"Dense deposit disease associated with monoclonal gammopathy of undetermined significance","volume":"56","author":"Sethi","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2020.11.010_bib59","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.2215\/CJN.06180710","article-title":"Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?","volume":"6","author":"Bridoux","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib60","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 glomerulonephritis associated with monoclonal gammopathy: a case series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2020.11.010_bib61","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib62","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 glomerulopathy associated with monoclonal Ig is a distinct subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.11.010_bib63","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both monoclonal and polyclonal immunoglobulin contingents mediate complement activation in monoclonal gammopathy associated-C3 glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.kint.2020.11.010_bib64","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0076-6879(85)16008-8","article-title":"Light chains of human immunoglobulins","volume":"116","author":"Solomon","year":"1985","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.kint.2020.11.010_bib65","doi-asserted-by":"crossref","first-page":"F82","DOI":"10.1152\/ajprenal.00091.2008","article-title":"Silencing megalin and cubilin genes inhibits myeloma light chain endocytosis and ameliorates toxicity in human renal proximal tubule epithelial cells","volume":"295","author":"Li","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2020.11.010_bib66","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1681\/ASN.2012040388","article-title":"Mechanisms of light chain injury along the tubular nephron","volume":"23","author":"Sanders","year":"2012","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib67","first-page":"F246","article-title":"Myeloma light chains are ligands for cubilin (gp280)","volume":"275","author":"Batuman","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.kint.2020.11.010_bib68","first-page":"223","article-title":"Endocytic receptors in the renal proximal tubule","volume":"27","author":"Christensen","year":"2012","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.kint.2020.11.010_bib69","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/ki.1987.286","article-title":"Human Bence Jones protein toxicity in rat proximal tubule epithelium in\u00a0vivo","volume":"32","author":"Sanders","year":"1987","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.11.010_bib70","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1172\/JCI119218","article-title":"Localization of a single binding site for immunoglobulin light chains on human Tamm-Horsfall glycoprotein","volume":"99","author":"Huang","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2020.11.010_bib71","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/S0002-9440(10)64142-9","article-title":"Mapping the binding domain of immunoglobulin light chains for Tamm-Horsfall protein","volume":"58","author":"Ying","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2020.11.010_bib72","first-page":"336","article-title":"Myeloma cast nephropathy: immunohistochemical and lectin studies","volume":"1","author":"Start","year":"1988","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2020.11.010_bib73","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.2019003807","article-title":"Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study","volume":"135","author":"Royal","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib74","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/ki.1981.122","article-title":"Pathophysiology of acute Bence-Jones protein nephrotoxicity in the rat","volume":"20","author":"Weiss","year":"1981","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.11.010_bib75","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/ki.1983.144","article-title":"Myeloma kidney cast nephropathy in a rat model of multiple myeloma","volume":"24","author":"Smolens","year":"1983","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.11.010_bib76","doi-asserted-by":"crossref","first-page":"F1245","DOI":"10.1152\/ajprenal.00350.2002","article-title":"Role of MAPK pathways in light chain-induced cytokine production in human proximal tubule cells","volume":"284","author":"Sengul","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.kint.2020.11.010_bib77","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1681\/ASN.2006111299","article-title":"Immunoglobulin light chains generate hydrogen peroxide","volume":"18","author":"Wang","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib78","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1681\/ASN.2009101089","article-title":"Immunoglobulin light chains activate tubular epithelial cells through redox signaling","volume":"21","author":"Basnayake","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib79","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1182\/blood-2010-08-302505","article-title":"Immunoglobulin light chains activate nuclear factor-\u03baB in renal epithelial cells through a Src-dependent mechanism","volume":"117","author":"Ying","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ajpath.2011.09.017","article-title":"Pivotal role of apoptosis signal-regulating kinase 1 in monoclonal free light chain-mediated apoptosis","volume":"180","author":"Ying","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.kint.2020.11.010_bib81","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1172\/JCI125517","article-title":"Immunoglobulin light chains generate proinflammatory and profibrotic kidney injury","volume":"129","author":"Ying","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2020.11.010_bib82","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrneph.2017.10","article-title":"Crystal nephropathies: mechanisms of crystal-induced kidney injury","volume":"13","author":"Mulay","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib83","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2006-03-008953","article-title":"Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials","volume":"108","author":"Drayson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib84","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-020-0295-4","article-title":"Serum free light chain level at diagnosis in myeloma cast nephropathy\u2014a multicentre study","volume":"10","author":"Yadav","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.kint.2020.11.010_bib85","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1172\/JCI115629","article-title":"Pathobiology of cast nephropathy from human Bence Jones proteins","volume":"89","author":"Sanders","year":"1992","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2020.11.010_bib86","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1172\/JCI114474","article-title":"Mechanisms of intranephronal proteinaceous cast formation by low molecular weight proteins","volume":"85","author":"Sanders","year":"1990","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.kint.2020.11.010_bib87","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00330-017-5023-5","article-title":"Iodine-based contrast media, multiple myeloma and monoclonal gammopathies: literature review and ESUR Contrast Media Safety Committee guidelines","volume":"28","author":"Stacul","year":"2018","journal-title":"Eur Radiol"},{"key":"10.1016\/j.kint.2020.11.010_bib88","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(19)30014-6","article-title":"High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial","volume":"6","author":"Hutchison","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.kint.2020.11.010_bib89","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2020.11.010_bib90","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2215\/CJN.00650110","article-title":"The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies","volume":"5","author":"Fish","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib91","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1053\/j.semdp.2020.02.001","article-title":"A\u00a0practical approach to the pathology of renal intratubular casts","volume":"37","author":"Dvanajscak","year":"2020","journal-title":"Semin Diagn Pathol"},{"key":"10.1016\/j.kint.2020.11.010_bib92","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1053\/j.ajkd.2019.02.010","article-title":"Paraneoplastic cast nephropathy associated with pancreatic mixed acinar-neuroendocrine carcinoma: a case report","volume":"74","author":"Nasr","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2020.11.010_bib93","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.3109\/10428194.2015.1040011","article-title":"Clinical and prognostic differences among patients with light chain deposition disease, myeloma cast nephropathy and both","volume":"56","author":"Zand","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.kint.2020.11.010_bib94","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1681\/ASN.V1271482","article-title":"Renal monoclonal immunoglobulin deposition disease: the disease spectrum","volume":"12","author":"Lin","year":"2001","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib95","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/modpathol.2017.124","article-title":"Intratubular amyloid in light chain cast nephropathy is a risk factor for systemic light chain amyloidosis","volume":"31","author":"Gibier","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.kint.2020.11.010_bib96","first-page":"484","article-title":"Pathogenesis and treatment of myeloma kidney","volume":"124","author":"Sanders","year":"1994","journal-title":"J\u00a0Lab Clin Med"},{"key":"10.1016\/j.kint.2020.11.010_bib97","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.ackd.2012.06.001","article-title":"Current approach to diagnosis and management of acute renal failure in myeloma patients","volume":"19","author":"Leung","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.kint.2020.11.010_bib98","first-page":"189","article-title":"Myeloma light chain cast nephropathy, a review","volume":"32","author":"Sathick","year":"2019","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib99","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.2215\/CJN.12231212","article-title":"Kidney disease and multiple myeloma","volume":"8","author":"Heher","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib100","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1038\/ki.2008.356","article-title":"Bisphosphonate nephrotoxicity","volume":"74","author":"Perazella","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.11.010_bib101","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ajh.21922","article-title":"High-dose glucocorticoids improve renal failure reversibility in patients with newly diagnosed multiple myeloma","volume":"86","author":"Bayraktar","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2020.11.010_bib102","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/leu.2012.182","article-title":"The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma","volume":"27","author":"Dimopoulos","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.kint.2020.11.010_bib103","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib104","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2017.76.1742","article-title":"Pomalidomide plus low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma and renal impairment: results from a phase II trial","volume":"36","author":"Dimopoulos","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2020.11.010_bib105","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2020.11.010_bib106","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.clml.2019.04.018","article-title":"Carfilzomib-dexamethasone versus bortezomib-dexamethasone in relapsed or refractory multiple myeloma: updated overall survival, safety, and subgroups","volume":"19","author":"Orlowski","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.kint.2020.11.010_bib107","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.kint.2020.11.010_bib108","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.11.010_bib109","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.11.010_bib110","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2020.11.010_bib111","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2020.11.010_bib112","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cncr.20888","article-title":"Bortezomib in recurrent and\/or refractory multiple myeloma: initial clinical experience in patients with impaired renal function","volume":"103","author":"Jagannath","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.kint.2020.11.010_bib113","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1182\/blood-2006-09-046409","article-title":"Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study","volume":"109","author":"Chanan-Khan","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.kint.2020.11.010_bib114","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3324\/haematol.11463","article-title":"Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma","volume":"92","author":"Ludwig","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2020.11.010_bib115","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study","volume":"22","author":"San-Miguel","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.kint.2020.11.010_bib116","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3816\/CLM.2009.n.059","article-title":"Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors","volume":"9","author":"Dimopoulos","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.kint.2020.11.010_bib117","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0609.2009.01385.x","article-title":"Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA","volume":"84","author":"Morabito","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.kint.2020.11.010_bib118","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1200\/JCO.2010.28.1238","article-title":"Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study","volume":"28","author":"Ludwig","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.kint.2020.11.010_bib119","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.24335","article-title":"Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis","volume":"91","author":"Dimopoulos","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2020.11.010_bib120","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2020.11.010_bib121","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.kint.2020.11.010_bib122","doi-asserted-by":"crossref","first-page":"e277","DOI":"10.3324\/haematol.2018.191122","article-title":"Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma","volume":"103","author":"Rocchi","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.kint.2020.11.010_bib123","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1681\/ASN.2010080857","article-title":"Early reduction of serum-free light chains associates with renal recovery in myeloma kidney","volume":"22","author":"Hutchison","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib124","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-143-11-200512060-00005","article-title":"Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial","volume":"143","author":"Clark","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2020.11.010_bib125","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/ki.2008.108","article-title":"Improvement of cast nephropathy with plasma exchange depends on the diagnosis and on reduction of serum free light chains","volume":"73","author":"Leung","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2020.11.010_bib126","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1056\/NEJMc1101834","article-title":"Renal improvement in myeloma with bortezomib plus plasma exchange","volume":"364","author":"Burnette","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2020.11.010_bib127","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1681\/ASN.2006080821","article-title":"Efficient removal of immunoglobulin free light chains by haemodialysis for multiple myeloma: in\u00a0vitro and in\u00a0vivo studies","volume":"18","author":"Hutchison","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib128","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2215\/CJN.04590908","article-title":"Treatment of acute renal failure secondary to multiple myeloma with chemotherapy and extended high cut-off haemodialysis","volume":"4","author":"Hutchison","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib129","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00277-011-1383-0","article-title":"Extracorporeal light chain elimination: high cut-off (HCO) haemodialysis parallel to chemotherapy allows for a high proportion of renal recovery in multiple myeloma patients with dialysis-dependent acute kidney injury","volume":"91","author":"Heyne","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.kint.2020.11.010_bib130","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1093\/ndt\/gfr773","article-title":"Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis","volume":"27","author":"Hutchison","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2020.11.010_bib131","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ajh.24035","article-title":"Bortezomib-based therapy combined with high cut-off haemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment","volume":"90","author":"Zannetti","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.kint.2020.11.010_bib132","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154993","article-title":"Impact of high-cut-off dialysis on renal recovery in dialysis-dependent multiple myeloma patients: results from a case-control study","volume":"11","author":"Gerth","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2020.11.010_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0159942","article-title":"Therapeutic efficacy and cost effectiveness of high cut-off dialyzers compared to conventional dialysis in patients with cast nephropathy","volume":"11","author":"Curti","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2020.11.010_bib134","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000481461","article-title":"Effectiveness of IHD with adsorptive PMMA membrane in myeloma cast nephropathy: a cohort study","volume":"46","author":"Sens","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib135","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/ndt\/gfr180","article-title":"Online high-efficiency haemodiafiltration achieves higher serum free light chain removal than high-flux haemodialysis in multiple myeloma patients: preliminary quantitative study","volume":"26","author":"Granger Vall\u00e9e","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.kint.2020.11.010_bib136","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140463","article-title":"Effectiveness of haemodiafiltration with heat sterilized high-flux polyphenylene HF dialyzer in reducing free light chains in patients with myeloma cast nephropathy","volume":"10","author":"Rousseau-Gagnon","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.kint.2020.11.010_bib137","first-page":"251","article-title":"A\u00a0novel option for reducing free light chains in myeloma kidney: supra-hemodiafiltration with endogenous reinfusion (HFR)","volume":"28","author":"Pasquali","year":"2015","journal-title":"J\u00a0Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib138","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1179\/1607845412Y.0000000003","article-title":"Use of continuous venovenous hemofiltration for acute renal failure due to multiple myeloma cast nephropathy","volume":"17","author":"Mehta","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.kint.2020.11.010_bib139","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S0272-6386(97)90083-4","article-title":"Hemodialysis: an appropriate therapy in myeloma-induced renal failure","volume":"30","author":"Sharland","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2020.11.010_bib140","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2215\/CJN.06290615","article-title":"Trends in survival and renal recovery in patients with multiple myeloma or light-chain amyloidosis on chronic dialysis","volume":"11","author":"Decourt","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2020.11.010_bib141","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1053\/j.ajkd.2016.12.023","article-title":"Kidney transplantation for kidney failure due to multiple myeloma: case reports","volume":"69","author":"Le","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2020.11.010_bib142","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1034\/j.1600-0609.2000.90221.x","article-title":"Renal failure in multiple myeloma: reversibility and impact on the prognosis","volume":"65","author":"Knudsen","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.kint.2020.11.010_bib143","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/ejh.12644","article-title":"Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury","volume":"96","author":"Yadav","year":"2016","journal-title":"Eur J Haematol"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820314058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253820314058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:57:28Z","timestamp":1758761848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253820314058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":143,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0085253820314058"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2020.11.010","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of acute kidney injury in symptomatic multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2020.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}